eBook: Allogeneic Cell Therapies Commercialization Strategies

1 Min Read

17-6-Allogeneic-eBook-229x300.jpgManufacturers of allogeneic cell therapies face development and commercialization challenges unlike those of traditional cell therapies. In a discussion with Phil Vanek of GE Healthcare, we outline several of the key challenges of processing these products and bringing them to market. Approaches for reducing development costs and lowering pricing are highlighted, and a separate analysis presents three pricing models specific for allogeneic “off the shelf” cell products.

You May Also Like